Table 3.

Proportion of participants who achieved ≥50% reduction in morning window hormone values or a return to normal values

Parameter, n/N (%)	All participants
≥50% reduction from baseline
ACTH	5/8 (63)
17-Hydroxyprogesterone	6/8 (75)
Androstenedione	4/8 (50)
Testosterone (females)	3/5 (60)
Androstenedione/testosterone ratio (males)	2/3 (67)
Return to normal valuesa
Androstenedione	3/6 (50)
Testosterone (females)	1/2 (50)
Androstenedione/testosterone ratio (males)	2/3 (67)

Abbreviations: ACTH, adrenocorticotropic hormone; ULN, upper limit of normal.

In the subset of participants who had baseline androstenedione or (female) testosterone values >1.2 × ULN or (male) androstenedione/testosterone ratio ≥0.5 at baseline. ULN was defined as follows: androstenedione (females aged 14-15), 200 ng/dL; androstenedione (females aged 16-17), 212 ng/dL; androstenedione (males aged 14-15), 94 ng/dL; androstenedione (males aged 16-17), 113 ng/dL; total testosterone (females), 76 ng/dL; total testosterone (males aged 14-15), 800 ng/dL; total testosterone (males aged 16-17), 827 ng/dL; and androstenedione/testosterone ratio (males), 0.5.